Adaptive Biotechnologies (ADPT) EV to EBITDA (2019 - 2026)

Adaptive Biotechnologies has disclosed EV to EBITDA across 8 years of filings, most recently posting 195.01 for Q2 2026.

• In Q2 2026, EV to EBITDA rose 24.88% year-over-year to 195.01; the TTM figure through Jun 2026 stood at 86.57 (up 271.98% YoY), while the FY2025 annual figure was 89.49, up 986.38% from the prior year.
• EV to EBITDA came in at 195.01 for Q2 2026 at Adaptive Biotechnologies, down from 165.28 in the prior quarter.
• In the past five years, EV to EBITDA ranged from a high of 268.34 in Q4 2025 to a low of 387.29 in Q4 2024.
• Average EV to EBITDA over 5 years is 36.51, with a median of 18.74 recorded in 2022.
• The largest YoY upside for EV to EBITDA was 288.47% in 2025 against a maximum downside of 2202.81% in 2025.
• Over 5 years, EV to EBITDA stood at 15.19 in 2022, then slumped by 140.99% to 36.6 in 2023, then plunged by 958.29% to 387.29 in 2024, then soared by 169.29% to 268.34 in 2025, then sank by 172.67% to 195.01 in 2026.
• Per Business Quant data, the three most recent EV to EBITDA figures were 195.01 in Q2 2026, 165.28 in Q1 2026, and 268.34 in Q4 2025.